DruQuaR

Drug Quality and Registration (DruQuaR) carries out fundamental and applied research in the fields of pharmaceutical analytics and regulatory affairs.

[DruQuaR @DruQuaR]

Following EU AI act, EMA and HMA have proposed workplan to balance the risk-benefits of AI in drug development. The workplan addresses 4 critical AI dimensions: policies, tools, training and experiments. https://t.co/IdnHulqAPq

[DruQuaR @DruQuaR]

SDISCO consortium members compared different techniques for the chiral separation of lactam-based P2RX7-antagonists.
https://t.co/XRZgF7Dgqs

[DruQuaR @DruQuaR]

Currently ongoing (also online): second WHO symposium on the future of health systems in a digital era.
Generative AI, digital health, big data, One Health digital technologies, … : sustainability of health systems by intelligent data use.

https://t.co/YAaW4841Wr

[S-DISCO @s_disco_]

UN highlights importance of sustainable wastewater treatment. Reuse or environmental release of insufficiently treated WW increases the risk of pharmaceutical pollution, undermining human and ecosystem health.
https://t.co/akTSHrfuWz

[DruQuaR @DruQuaR]

Center of Excellence in Neglected and Tropical Diseases (CENTD) meeting 19&20 June 2023: attention to #sustainability aspects of #anthelmintic medicines, including #environmental impact and #quality.

[S-DISCO @s_disco_]

@EU_Commission released proposal for major change in the human pharmaceutical legislation, undoubtedly making the system more sustainable. One of the key changes is the importance of the environmental risk assessment, in line with the European Green Deal. https://t.co/eYRDl9eqT7

[DruQuaR @DruQuaR]

We are proud to announce that DruQuaR researcher @AntonSpiegeleer won the Faculty PhD thesis prize for Clinical and Translational Sciences. A strong start for @trigg_research

[TRIGG @trigg_research]

Our Anton De Spiegeleer won the Faculty PhD Thesis Prize 2021-2022 for Clinical and Translational Science. His work about the mechanisms of sarcopenia was much appreciated by the jury. A motivation for all TRIGG-researchers to build further on translational sarcopenia research.

[DruQuaR @DruQuaR]

Our most recent publication addresses some of the #pitfalls frequently encountered in #UPLC-MSMS #peptidomics. We hope this can help fellow scientists and improve the #sustainability of #research!
https://t.co/P6RR3W36Hl

[Sustainable Drug Discovery Days @sdiscodays]

💊We are excited to announce S-DISCO Days in Gdańsk, Poland on April 3-4 2023.
🌱This conference will bring together experts in sustainability and drug discovery for talks, panel discussions, and networking opportunities.
📢Stay tuned for more information on speakers and program.

[Sustainable Drug Discovery Days @sdiscodays]

We're honored to have Prof. Dr. Joachim Jose as our first speaker, sharing his expertise in his talk "Towards the Development of Sustainable Tools for Drug Discovery."

Get ready to dive into the world of sustainable drug discovery with this and many other insightful discussions!

[DruQuaR @DruQuaR]

Bacterial peptides that can impact our immune system! Read our exciting results about quorum sensing peptides and the immune system in Biomolecules #peptides #bacteria #immune system #quorum sensing #TRIGG
https://t.co/gkVqIOZpYV

[DruQuaR @DruQuaR]

Animal testing in drug development is no longer an absolute requirement in the US: are we ready to (completely) replace animal testing with pharmaceutical data-intelligence and in-vitro systems?
https://t.co/sQJwK6k6cJ

[DruQuaR @DruQuaR]

We published a manuscript addressing the environment-functionality-cost balance of an analytical reagent.

Read it for free using the link below!
https://t.co/ERSmikFFIh

[DruQuaR @DruQuaR]

Draft @US_FDA guidance provides novel science-based statistical approaches to bioequivalence, opening avenues beyond the traditional average #bioequivalence approach.

[DruQuaR @DruQuaR]

First FMT product approved by @US_FDA: #Rebyota is prepared from donated stool and rectally administred after antibiotic treatment. Inspiration for SoHo-regulation proposal: FMT products are medicines, as recommended by our group and applied in most of EU.
https://t.co/eex5KTqXhF

[DruQuaR @DruQuaR]

Regulations are propelling sustainable pharmaceutics forward: ICH has adopted the Q13 guideline about continuous manufacturing, which can now move to its regulatory implementation in the ICH regions.

@EMA_News @US_FDA @ICH_news

https://t.co/3OSkVxn8Ar

[DruQuaR @DruQuaR]

We need to apply a #OneHealth approach to cope with #AMR all sectors must be involved in strengthening preventive measures. Safe vaccines, rational use of antimicrobials, sound antimicrobials waste management and discovery of novel targets to develop safer medicines are key.

[EU Medicines Agency @EMA_News]

#JustPublished!

Global medicine regulators share best practices to combat #AntimicrobialResistance, a silent pandemic.

Read the latest #ICMRA report now:

#AMR #WAAW #ICMRA

[DruQuaR @DruQuaR]

Gut #microbiota has been suggested to contribute to age-associated muscle wasting In our recent publication, we uncover the quorum sensing #peptide iAM373 as a hitherto unknown contributor to #sarcopenia. @trigg_research

https://t.co/AJRaT6UkMn

[DruQuaR @DruQuaR]

EMA-HMA report: FMT are in majority of EU considered medicinal products. Logical observation, in line with our view. We argue in favour of ATMP with the flexibility and efficacy-safety assurance it provides.
https://t.co/tE7mT2EH7h
https://t.co/VWYiobfoGm
https://t.co/ZEkMdI1Yrp

[S-DISCO @s_disco_]

Today, the S-DISCO #students visited the #Ecotron of @CMK_UHasselt. There, the effects of future climate on agroecosystems are investigated and new mitigation strategies explored. Thank you prof. Francois Rineau for this very interesting visit!
#SDISCO #sustainability